All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Approvals & Labels

NICE approves AstraZeneca's Imfinzi-Imjudo dual immunotherapy for advanced hepatocellular carcinoma based on Ph3 HIMALAYA results
Antibody, cancer, immunotherapy, hepatocellular carcinoma, combination therapy, liver cancer - Read more

THE GOOD
Business Development & Partnerships

Kissei, Viridian partner on thyroid eye disease drugs for Japan; $70M upfront, $315M in milestones
Licensing deal, rare disease, antibody, milestone payments, Asia, commercialization - Read more

Madrigal, CSPC partner on oral GLP-1 for MASH; $120M upfront, $2B+ in potential milestones
Licensing deal, metabolic disease, small molecule, GLP-1, milestone payments, global - Read more

Nautilus Biotechnology, Allen Institute partner to study tau proteins in Alzheimer's disease
Research collaboration, neurological, proteomics, Alzheimer's disease, R&D - Read more

Dr. Falk Pharma, Allianthera partner to develop novel AhR agonist for IBD; deal includes signing fee, milestones, royalties
Co-development, licensing deal, inflammatory bowel disease, small molecule, milestone payments - Read more

Formation Bio, IMIDomics partner on anti-CD226 mAb for autoimmune diseases; deal includes equity, milestones and royalties
Licensing deal, autoimmune, monoclonal antibody, equity investment, milestone payments - Read more

PRESENTED BY PROMOVEO HEALTH
Contract Sales Reps. Half the Budget. Double the Impact.

Stretching your commercial budget?

Get two flex-time reps for the price of one full-time with Promoveo Health.

We build agile field teams that scale up or down based on your brand’s needs — fast.

See how flexible can work - click here to learn more.

✅ More Good News ✅

THE GOOD
Clinical Trials

Exonate advances EXN407, SRPK1 inhibitor eyedrops, to Ph2b trial for diabetic retinopathy after positive Ph1b/2a results
Small molecule, metabolic, SRPK1 inhibitor, diabetic retinopathy, eye drop, mRNA splicing - Read more

Alfasigma's Filgotinib meets Ph3 endpoint for axial spondyloarthritis, targeting JAK1 pathway across disease spectrum
Small molecule, autoimmune, JAK inhibitor, axial spondyloarthritis, rheumatology, oral therapy - Read more

Biogen, Eisai's Leqembi shows four-year efficacy data slowing Alzheimer's disease progression in Ph3 extension study
Antibody, neurological, monoclonal antibody, Alzheimer's disease, amyloid target, disease progression - Read more

AbbVie's RINVOQ® (upadacitinib) achieves significant hair regrowth in Ph3 trial for severe alopecia areata
Small molecule, autoimmune, JAK inhibitor, alopecia areata, immune-mediated disease, hair loss - Read more

NewAmsterdam Ph3 BROADWAY trial shows obicetrapib reduces Alzheimer's disease biomarkers in cardiovascular disease patients
Small molecule, neurological, CETP inhibitor, Alzheimer's disease, cardiovascular, biomarkers - Read more

THE GOOD
Earnings & Finances

GSK maintains £40B ($53B) 2031 sales projection despite FDA committee rejection of cancer drug Blenrep
Monoclonal antibody, respiratory disease, oncology, strategic, financial, competitive - Read more

THE GOOD
Fundraises

Larimar Therapeutics raises $60M public offering for rare disease treatments and pipeline development
Rare disease, clinical-stage, biotechnology, complex diseases - Read more

Kinvard Bio receives $2.7M CARB-X funding for broad-spectrum antibiotic development
Infectious disease, small molecule, antibiotics, antimicrobial resistance, preclinical - Read more

LIfT BioSciences receives €12M ($13.9M) grant for neutrophil immunotherapy clinical trials in solid tumors
Oncology, cell therapy, immunotherapy, solid tumors, neutrophil platform - Read more

THE GOOD
Investments

Celltrion named preferred bidder for US biologics plant, investing $504M to mitigate import tariffs
Biosimilars, oncology, autoimmune, strategic, operational, major transaction - Read more

THE GOOD
Politics & Policy

Teva shrugs off pharmaceutical tariff threat, citing US-based manufacturing and limited China/India exposure
Generic drugs, branded drugs, operational, regulatory, financial impact - Read more

Senate confirms Susan Monarez as CDC Director despite budget cuts and vaccine controversy
Public health policy, government leadership, regulatory, operational, organizational restructuring - Read more

THE GOOD
Research

Profluent's OpenCRISPR-1, first AI-designed CRISPR genome editor, demonstrates successful human genome editing in Nature publication
Gene therapy, genetic disorders, CRISPR, genome editing, artificial intelligence, immunogenicity - Read more

THE GOOD
Strategic Plans

GSK plans "tens of billions" US investment amid Trump tariffs, discontinues multiple pipeline assets
Monoclonal antibody, oncology, infectious disease, strategic, operational, financial - Read more

PRESENTED BY YOU?
Get the attention of 2000+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

THE BAD
Approvals & Labels

FDA misses Coya's ALS drug review deadline, citing resource constraints; decision expected by August 29
ALS therapy, neurological, regulatory delay, rare disease, operational - Read more

THE BAD
Clinical Trials

GSK's cobolimab fails Ph3 trial in non-small cell lung cancer, missing survival endpoint for TIM-3 inhibitor
Antibody, cancer, monoclonal antibody, non-small cell lung cancer, checkpoint inhibitor, immuno-oncology - Read more

Vyne Therapeutics' BET inhibitor repibresib fails Ph2 trial for non-segmental vitiligo, raising safety concerns
Small molecule, autoimmune, BET inhibitor, vitiligo, topical therapy, phase 2 failure - Read more

THE BAD
Earnings & Finances

Takeda faces Vyvanse generic erosion with 8.4% revenue drop, explores DTC model amid US pricing uncertainties
ADHD medication, autoimmune, financial, operational, pricing strategy - Read more

THE BAD
Regulatory

FDA's CDER head Tidmarsh temporarily takes charge of CBER following Prasad's sudden resignation
Gene therapy, rare disease, regulatory, leadership change - Read more

THE UGLY
No Ugly News today!

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here